Research

Posted: Apr 2, 2014 by Yariv Houvras

Update on ITOG’s First Clinical Trial

ITOG's first clinical trial has reached 50% of patient accrual. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University,examines whether patients who had progression of their thyroid cancer on a VEGFR inhibitor benefit from treatment with Cabozantinib.

Posted: Feb 3, 2014 by Yariv Houvras

Lenvatinib Extends PFS in Differentiated Thyroid Cancer

The phase III SELECT trial of the investigational agent lenvatinib (E7080) met its primary endpoint of progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), according to Eisai Inc., the company that is developing the agent.

Posted: Jun 13, 2013 by Yariv Houvras

Sorafenib Improves Thyroid Cancer Outcomes

(ASCO, June 2, 2013) A large phase III clinical trial reported that sorafenib improves progression free survival for patients with radioactive iodine refractory, differentiated thyroid cancer.

Posted: Jun 11, 2013 by Yariv Houvras

Medullary thyroid cancer : Mutations predict response to oral chemotherapy

For advanced non-resectable MTC (medullary thyroid cancer), there are now two FDA-approved drugs, vandetanib (Caprelsa) and cabozantinib (Cometriq).  At the 2013 American Society of Clinical Oncology meeting in Chicago, ITOG investigators working with Exelixis, Inc.

Posted: Apr 18, 2013 by Yariv Houvras

ITOG Opens First Clinical Trial

ITOG is poised to open it’s first clinical trial for treatment of differentiated thyroid cancer. This multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, will examine whether patients who had progression of their thyroid cancer on a VEGR inhibitor benefit from...

Posted: Mar 31, 2012 by Yariv Houvras

ITOG Enters Collaborative Agreement With ACCRU to Perform Clinical Trials

ITOG leaders sign Collaborative Agreement with ACCRU.
March, 2012: The ITOG Board of Directors endorsed a partnership with Academic and Community Cancer Research United (ACCRU) an affiliate of Mayo Clinic, Rochester, to conduct clinical trials.  ACCRU was selected after an extensive search to identify a partner to provide robust infrastructure...

Pages

Contact

International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495